NCT00474760View on ClinicalTrials.gov

Study Of Anti-IGF-IR CP-751,871 In Patients With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

January 31, 2011

Study Completion Date

October 31, 2012

Conditions
Sarcoma, Ewing's
Interventions
DRUG

CP-751,871

Currently dosing at 20 mg/kg, IV on day 1 of each 28 day cycle until progression or unacceptable toxicity

Trial Locations (3)

55905

Pfizer Investigational Site, Rochester

48109-0848

Pfizer Investigational Site, Ann Arbor

SM2 5PT

Pfizer Investigational Site, Sutton

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00474760 - Study Of Anti-IGF-IR CP-751,871 In Patients With Solid Tumors | Biotech Hunter | Biotech Hunter